Skip to main content
. 2003 Nov 14;8(Suppl 1):S36–S40. doi: 10.1046/j.1440-1843.2003.00522.x

Table 1.

Outcome studies in SARS

Study No. of patients Virological documentation Follow up duration End‐points Prognostic factors implicated
ICU admission Ventilation support Mortality
Lee et al. 3 138 NR NR 32(23.2%) 19 (13.8%)  3.6% (21‐day) Age, peak LDH, neutrophil count above normal
Booth et al. 4 144 NR 21 days 29 (20%) 20 (14%)  6.5% (21‐day) Comorbidity (Diabetes)
Wong et al. 5 157 87.9% Median 26 days NR NR NR Age, initial LDH level, low initial CD4, CD8 count
Chan et al. 6 115 89% Median 62 days 39 (34%) 30 (26%) 10% (21‐day) Age, comorbidity (Diabetes, heart disease)
Peiris et al. 7  75 93% 24 days 24 (32%) 19 (25%) (ARDS: 20%)  6.7% (21‐day) Age, comorbidity (hepatitis B)
Tsui et al. 2 323 89% <5 weeks 67 (21%) 42 (13%) NR Age, initial LDH, neutrophil count
Lew et al. 8 199 NR 28 days 46 (23%) 39 (19.5%) (ALI/ARDS: 22.6%) 10.1% (28‐day) APACHE II score, baseline PaO2/FiO2 ratio
Fowler et al. 9 196 NR 28 days 38 (19%) 29 (14.8%)  6.6% (28‐day) Age, Diabetes, bilateral lung infiltrates

ICU, intensive care unit; ALI, acute lung injury; ARDS, acute respiratory distress syndrome; NR, not reported.